Follow
Andreas Zaragkoulias, PhD
Andreas Zaragkoulias, PhD
Biomedical Research Scientist, Molecular and Cell Cancer Biology, Antibody Engineering
Verified email at cardiff.ac.uk - Homepage
Title
Cited by
Cited by
Year
Reduced dosage of ERF causes complex craniosynostosis in humans and mice and links ERK1/2 signaling to regulation of osteogenesis
SRF Twigg, E Vorgia, SJ McGowan, I Peraki, AL Fenwick, VP Sharma, ...
Nature genetics 45 (3), 308-313, 2013
1632013
Semaphorin-7a reverses the ERF-induced inhibition of EMT in Ras-dependent mouse mammary epithelial cells
M Allegra, A Zaragkoulias, E Vorgia, M Ioannou, G Litos, H Beug, ...
Molecular biology of the cell 23 (19), 3873-3881, 2012
512012
The SARS-CoV2 envelope differs from host cells, exposes procoagulant lipids, and is disrupted in vivo by oral rinses
Journal of Lipid Research 63 (6), 2022
342022
EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas
W Hill, A Zaragkoulias, B Salvador-Barbero, GJ Parfitt, M Alatsatianos, ...
Current biology 31 (12), 2550-2560. e5, 2021
322021
Suppression of Fgf2 by ETS2 repressor factor (ERF) is required for chorionic trophoblast differentiation
E Vorgia, A Zaragkoulias, I Peraki, G Mavrothalassitis
Molecular Reproduction and Development 84 (4), 286-295, 2017
82017
The SARS-CoV2 envelope is distinct from host membranes, exposes pro-coagulant lipids, and can be inactivated in vivo by surfactant-containing oral rinses
Z Saud, VJ Tyrrell, A Zaragkoulias, MB Protty, E Statkute, A Rubina, ...
medRxiv, 2022.02. 16.22270842, 2022
2022
Antibody Therapeutic for the Treatment of HCMV
GB Patent PCT/GB2022/050217 | 0310P/W O, 2022
2022
The system can't perform the operation now. Try again later.
Articles 1–7